FIRST REPORT OF THE ANTICANCER EFFICIENCY OF AGARICUS BRASILIENSIS MUSHROOM ON HUMAN EMBRYONIC LIVER WRL68 AND HUMAN PANCREATIC ASPC-1 CANCER CELLS THERAPY

Abstract

Mushrooms are food traditionally consumed in Asia, Europe and America. They are being studied for medicinal benefits. Extensive studies have shown that Agaricus brasiliensis mushroom used as a medical productto combat cancers. Our data reveal that the determined inhibitory concentration fifty(IC50) values were observed maximum dose responses (IC50) of WRL68 andAsPC-1 cancer cells reported of 172.6 µg/ml and 158.2 µg/ml respectively at 2.23 and 2.1 µg/ml ethanolic mushroom concentrations. The highly cytotoxic activity of the extract on growth inhibition AsPC-1 and WRL68were generally observed 97.9% and 95% at extract concentrations of 25 µg/ml and 50µg/ml respectively. Finally, Phytochemical profile of Agaricus brasiliensis mushroom extract found to beflavonoids, glycosides, saponins, phenols,alkaloids, tannins.The extracts of Agaricus brasiliensiswas tested throughGas Chromatography-Mass(GC-MS). There were five different compounds analyzed from the extracts of Agaricus brasiliensis. The compounds in the ethanolic extract of A. brasiliensis mushroom were comprised mostly of Acetic acid ethyl ester(38.39%),followed by(3-Methyl-oxiran-2-yl)-methanol (34.71%), Chlorbromuron (22.86%), n-Hexadecanoic acid (3.85%) and Heptane, 1-(1-butenyloxy) (0.19%). However, no studies were done using Agaricus brasiliensismushroom extract against WRL68 and AsPC-1 human cell lines. Therefore, the anticancer efficiency of Agaricus brasiliensis mushroom on human embryonic liver WRL68 andhuman pancreatic AsPC-1 cancer cellstherapy is being reported for the first time in the current study.